Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 11326154
    Abstract: The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, and affinity chromatography matrices comprising such fusion proteins, as well as methods of using same.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 10, 2022
    Assignee: Merck Patent GmbH
    Inventors: Martin Zillmann, Joe Orlando
  • Patent number: 11324778
    Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 10, 2022
    Assignee: International Stem Cell Corporation
    Inventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
  • Patent number: 11327082
    Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: May 10, 2022
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Aline Pehla, Stefan Kirsch, Darius Wilson
  • Patent number: 11319345
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: May 3, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Patent number: 11312788
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 26, 2022
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Patent number: 11311523
    Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below wherein R5 in the group represented by Formula (3) is hydrogen.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 26, 2022
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yoshinori Fukui, Takehito Uruno
  • Patent number: 11299555
    Abstract: This method for aiding Alzheimer's detection provided by the present invention includes: determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. A difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing Alzheimer's.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 12, 2022
    Assignees: Toagosei Co., LTD, National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Makoto Sawada, Tetsuhiko Yoshida
  • Patent number: 11299762
    Abstract: Motion detector comprising a flexible support (1,5) adapted to hold at least one object (6-9), a sensor (4) for measuring the displacement of said support (1) and processing means for differentiating the fluctuations of said support (1) from those induced by said object (6-9).
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: April 12, 2022
    Assignee: ECOLE POLYTECHNIOUE FEDERALE DE
    Inventors: Sandor Kasas, Giovanni Longo, Giovanni Dietler, Livan Bladimir Alonso Sarduy
  • Patent number: 11293932
    Abstract: Disclosed are methods and systems for determining concentrations of a target molecule and a variant thereof in a sample. The sample can comprise or be suspected to comprise a target molecule and at least one variant thereof and is exposed to one or more recognition elements that bind to the target molecule and/or the at least one variant. A signal is detected that is associated with the binding of the target molecule and/or a signal is detected that is associated with the binding of the at least one variant to the one or more recognition elements. The concentration of the target molecule and/or the at least one variant thereof is determined based on the signals. The system can comprise a receiver adapted to receive a sample comprising or suspected to comprise a target molecule and the at least one variant thereof, the receiver comprising one or more recognition elements that bind to one or more epitopes in the target molecule and/or the at least one variant thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 5, 2022
    Assignee: North Carolina State University
    Inventors: Brian Michael Cummins, Frances Smith Ligler, Glenn Walker
  • Patent number: 11291997
    Abstract: A system for and methods of analyzing a test sample through the use of a rotary apparatus that includes a microfluidic paper-based apparatus (mPAD). The apparatus includes two or more layers that are rotatable with respect to one another. A middle layer may comprise a microfluidic apparatus having one or more reagent channels. Each of the reagent channels may include reagent dried on the surface of the channel, and, together with an absorption pad, may be aligned vertically with a sample chamber. Male and female engagement surfaces on each of the middle layer, the top layer, and the bottom layer interlock to secure each layers in vertical alignment so that fluid flows through the apparatus to contact a test sample with a reagent and facilitate detection of a target analyte in the test sample in the sample chamber.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: April 5, 2022
    Assignees: Colorado State University Research Foundation, The United States of America, as represented by the Secretary of Agriculture
    Inventors: Charles S. Henry, Rachel Feeny, Alan B. Franklin, Cody Carrell
  • Patent number: 11286289
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 29, 2022
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
  • Patent number: 11280788
    Abstract: Described is an assay for diagnosing an infection such as peritonitis in a subject. The assay includes a binding molecule, such as an antibody that specifically binds to an inflammatory marker in a sample from the subject, and a second binding molecule that binds to a marker indicative of a pathogen in the sample. For diagnosing peritonitis in a subject, the pathogen will be at least one bacterium and/or fungus. Typically, the assay will be incorporated into a lateral flow device and may include a binding molecule that specifically binds to an antigen indicative of the presence of a specific pathogen species. The described assay(s) may further include filter(s), enriching antigen(s), and buffer(s). Also described are methods of diagnosing and treating peritonitis in a subject who is a peritoneal dialysis patient that include utilizing the herein described assay(s) or assay kit(s) to analyze the subject's peritoneal dialysis effluent.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 22, 2022
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Tao Jiang, Changna Wang
  • Patent number: 11279768
    Abstract: This invention relates to antibodies to anti-cancer antibodies and uses thereof, including combination therapies and compositions. Combinations targeting the extrinsic, intrinsic, or common pro-apoptotic pathways are provided. Exemplary anti-cancer antibodies are differentially expressed in cancers, such as antibodies targeting the bind the antigens NPC-1, 16C3, or 31.1. Exemplary anti-cancer antibodies target lung cancer, ovarian cancer, cervical cancer, uterine cancer, pancreas cancer, breast cancer, and colon cancer.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: March 22, 2022
    Assignee: PRECISION BIOLOGICS, INC.
    Inventor: Philip M. Arlen
  • Patent number: 11275020
    Abstract: A lateral flow assay device includes several markers, a color bar, and/or a grayscale on the housing of the lateral flow assay device. The markers are used to assist in focusing a mobile device's camera on the control line of the lateral flow assay device. The markers may be used to adjust the perspective of an image taken from the control line and the test line of the lateral flow assay device. The markers may be used to locate the images of the control line, the test line, the color bar, and/or the grayscale on the image. The image of the color bar and the grayscale may be used to adjust the colors and intensity of the image. The images of the test line and the control line may then be used to determine the test results of the lateral flow assay device.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 15, 2022
    Inventor: Mehdi Hatamian
  • Patent number: 11275018
    Abstract: Reusable network of spatially-multiplexed microfluidic channels each including an inlet, an outlet, and a cuvette in-between. Individual channels may operationally share a main or common output channel defining the network output and optionally leading to a disposable storage volume. Alternatively, multiple channels are structured to individually lead to the storage volume. An individual cuvette is dimensioned to substantially prevent the formation of air-bubbles during the fluid sample flow through the cuvette and, therefore, to be fully filled and fully emptied. The overall channel network is configured to spatially lock the fluidic sample by pressing such sample with a second fluid against a closed to substantially immobilize it to prevent drifting due to the change in ambient conditions during the measurement. Thereafter, the fluidic sample is flushed through the now-opened valve with continually-applied pressure of the second fluid.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: March 15, 2022
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ramin Haghgooie, Kenneth T. Kotz, Robert Granier, Anne Celia Petrofsky
  • Patent number: 11266737
    Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 8, 2022
    Assignee: ARAVAX PTY LTD
    Inventors: Robyn Elizabeth O'Hehir, Sara Rachel Prickett, Jennifer May Rolland
  • Patent number: 11268963
    Abstract: Described are optical methods and reagents for sequencing polypeptides. A probe that exhibits different spectral properties when conjugated to different N-terminal amino acids is conjugated to the N-terminal amino acid of a polypeptide. Sequentially detecting one or more spectral properties of the probe conjugated to the N-terminal amino acid and cleaving the N-terminal amino acid produces sequence information of the polypeptide. The use of super-resolution microscopy allows for the massively parallel sequencing of individual polypeptide molecules in situ such as within a cell. Also described are probes comprising hydroxymethyl rhodamine green, an isothiocyanate group and a protecting group.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: March 8, 2022
    Inventor: Andrew Emili
  • Patent number: 11267879
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of hookworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample from a mammal that may also be infected with one or more of roundworm, whipworm, and heartworm. Confirmation of the presence or absence of hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 8, 2022
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Jinming Geng, David Allen Elsemore
  • Patent number: 11260389
    Abstract: A diagnostic cartridge and method of performing a diagnostic test are provided. The cartridge includes a body having a sample chamber for receipt of a sample, an analysis chamber, and a reagent-containing dispensing member. A valve member is coupled to the body for selective movement between first and second states. The valve member has a fluid passage with a hydroscopic, gas permeable vent. In the first state, the fluid passage is out of fluid communication with the sample chamber and is registered for fluid communication with the reagent-containing dispensing member. The vent prevents fluid from passing therethrough and allows air to vent therefrom as reagent flows into and fills the fluid passage. In the second state, the fluid passage remains in fluid communication with the reagent-containing dispensing member and is brought into fluid communication with the sample chamber to facilitate transporting the sample to the analysis chamber.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: March 1, 2022
    Assignee: CREGANNA UNLIMITED COMPANY
    Inventors: David W. Wright, Peter W. Kroehl, Paul S. Wright
  • Patent number: 11259739
    Abstract: The invention generally relates to medical kits, e.g., an immunotherapy treatment and testing kits, and more particularly to a method of using the kits and system for treating allergies.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: March 1, 2022
    Inventor: Eric R. Daines
  • Patent number: 11262359
    Abstract: A spectral reflectance imaging device for detecting nanoparticle exosome biomarker targets includes an illumination source that illuminates a substrate with a plurality of separate wavelengths of incoherent light. The substrate includes an oxide layer and a binding agent to selectively bind nanoparticle exosome biomarker targets to the substrate. An imaging device bindings the light reflected from or transmitted through the substrate and an image processing system detects the nanoparticle exosome biomarker targets a function of the change in reflective properties of the substrate.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 1, 2022
    Assignee: NanoView Biosciences, Inc.
    Inventors: George Daaboul, David S. Freedman
  • Patent number: 11261453
    Abstract: Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human ApoE protein. In some embodiments the polypeptide comprises ApoE2. In some embodiments the polypeptide comprises ApoE3. In some embodiments the polypeptide comprises ApoE4. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress Apo-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease. Also disclosed are methods of screening yeast cells to identify genetic suppressors or enhancers of ApoE-induced toxicity. Also disclosed are genetic suppressors or enhancers of ApoE-induced toxicity identified using the methods, and human homologs thereof. Also disclosed are methods of identifying compounds that modulate expression or activity of genetic modifiers of ApoE-induced toxicity.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 1, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Priyanka Narayan
  • Patent number: 11255857
    Abstract: The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 22, 2022
    Assignees: Aspira Women's Health Inc., The Johns Hopkins University
    Inventors: Zhen Zhang, Daniel W. Chan, Eric T. Fung, Zheng Wang, Fujun Zhang
  • Patent number: 11255854
    Abstract: The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: February 22, 2022
    Assignee: Zoetis Services LLC
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Jeremy Walker, Cristina Cuesico
  • Patent number: 11246880
    Abstract: Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 15, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Andrew P. Capaldi, James E. Hughes Hallett
  • Patent number: 11244763
    Abstract: Systems and methods are provided for predicting metastasis of a cancer in a subject. A plurality of data elements for the subject's cancer is obtained, including sequence features comprising relative abundance values for gene expression in a cancer biopsy of the subject, optional personal characteristics about the subject, and optional clinical features related to the stage, histopathological grade, diagnosis, symptom, comorbidity, and/or treatment of the cancer in the subject, and/or a temporal element associated therewith. One or more models are applied to the plurality of data elements, determining one or more indications of whether the cancer will metastasize. A clinical report comprising the one or more indications is generated.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: February 8, 2022
    Assignee: Tempus Labs, Inc.
    Inventors: Ashraf Hafez, Martin Christian Stumpe, Nike Beaubier, Daniel Neems, Caroline Epstein, Adrian William George Lange
  • Patent number: 11242515
    Abstract: Disclosed herein are methods for the isolation and purification of a botulinum neurotoxin (BoNT) protein, or a polypeptide comprising a receptor binding domain of BoNT, from a solution. The method comprises contacting the solution containing the protein or polypeptide to a matrix which has attached thereto a non-toxic non-hemagglutinin (NTNHA) under conditions appropriate for binding, washing the matrix to thereby remove unbound materials, and eluting the protein or polypeptide with a solution that dissociates the bound protein from the NTNHA. Conditions appropriate for binding are a pH of less than 7.5 (e.g, 6). Conditions appropriate for dissociation are a pH greater than or equal to 7.5 (e.g., 8). Compositions specific to the methods are also disclosed.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 8, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Min Dong, Sulyman Barkho, Liang Tao
  • Patent number: 11243215
    Abstract: In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 8, 2022
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Jesus Campagna, Tina Bilousova, Patricia R. Spilman, Peter James Heinzelman, Asa Hatami, Mohammad Parvez Alam
  • Patent number: 11236199
    Abstract: Disclosed herein is a very efficient method to make 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) from feedstocks comprised of furoates. When a feedstock comprised of methyl 5-methylfuran-2-carboxylate (MMFC) is used a product comprised of (5-(methoxycarbonyl)furan-2-carboxylic acid (MCFC) is obtained in high yield.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: February 1, 2022
    Assignee: Eastman Chemical Company
    Inventor: Mesfin Ejerssa Janka
  • Patent number: 11236128
    Abstract: Described herein is an operationally simple, one-pot solid-supported preparation of saturated stapled peptides. Following completion of ruthenium-catalysed metathesis, solid-phase transfer hydrogenation was achieved using triethylhydrosilane at elevated temperatures. The utility of the method has been demonstrated on 14- and 16-mer peptides to yield the corresponding cyclic a-helix stabilised stapled peptides.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: February 1, 2022
    Assignee: Agency for Science, Technology and Research
    Inventors: Tsz Ying Yuen, Charles William Johannes, Gerard Hilinski
  • Patent number: 11236138
    Abstract: An isolated peptide comprises a motif of RRWQW (SEQ ID NO: 1) for melanin polymerization and hair darkening is provided. Also disclosed herein are methods and compositions for hair darkening in a mammal subject.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 1, 2022
    Assignee: RENORIGIN INNOVATION INSTITUTE CO., LTD.
    Inventors: Hsiu-Chin Huang, Hsuan Lin
  • Patent number: 11226334
    Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 18, 2022
    Assignees: J-CHEMICAL, INC., OSAKA UNIVERSITY
    Inventors: Yuka Kobayashi, Kazutoshi Fujita, Norio Nonomura, Eiji Miyoshi
  • Patent number: 11226331
    Abstract: The present invention relates to controls which may be used to secure the results of multiplex analysis methods. The present invention thus relates to solid supports comprising one or several controls and their use in multiplex analysis methods to detect several analytes potentially present in a sample.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: January 18, 2022
    Assignee: BIO-RAD EUROPE GMBH
    Inventors: Christophe Rene Roger Vedrine, Nadine Marie Renee Lambert
  • Patent number: 11224668
    Abstract: The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 18, 2022
    Assignee: NEUROVATION LABS, INC.
    Inventor: Jennifer Perusini
  • Patent number: 11226343
    Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 18, 2022
    Assignees: BIOTHELIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LE RECHERCHE MEDICAL), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE DE LILLE
    Inventors: Philippe Lasalle, Sidney Chocron, Nathalie De Freitas Caires
  • Patent number: 11221341
    Abstract: Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A (SEQ ID NO.1) is determined.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: January 11, 2022
    Assignees: Commissariat a 1'Energie Atomique et aux Energies Alternatives, Centre Hospitalier Universitaire, Universite Grenoble Alpes, Institut National de la Sante et de la Recherche Medicale, Universite Paris Sud
    Inventors: Virginie Brun, Jérôme Garin, Christophe Bruley, Jamila Faivre, Jean-Pierre Zarski, Vincent Leroy
  • Patent number: 11221339
    Abstract: The present disclosure provides a rapid, scalable, and high-throughput method of identifying the precise regions in a receptor protein which are involved in binding of a molecule of interest. The method of the instant disclosure is useful where the crystal structure of a protein of interest is not available. Also provided are surface display libraries, and methods of making the same.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: January 11, 2022
    Assignee: INDIAN INSTITUTE OF SCIENCE
    Inventors: Raghavan Varadarajan, Tariq Ahmad Najar, Rohini Datta
  • Patent number: 11213579
    Abstract: Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 4, 2022
    Inventors: Boris Farber, Sof'ya Farber, Artur Viktorovich Martynov
  • Patent number: 11213567
    Abstract: A zinc-alpha-2-glycoprotein (ZAG) protein-derived peptide according to the present invention shows an expression reducing effect of various immune factors shown in acute or chronic atopic dermatitis, and has a decreased immune response and decreased IgE expression and thus may be used to prevent, treat or improve xeroderma or an abnormal skin barrier function such as atopic dermatitis, an allergic disease or inflammation.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 4, 2022
    Assignee: L&C Bio Co., LTD.
    Inventors: Eun Seong Lee, Hyung Gu Kim, Whan Chul Lee, Kee Won Lee
  • Patent number: 11215615
    Abstract: Provided are peptide biomarkers for diagnosis of allergy, monitoring development of clinical tolerance in an allergic individual, and predicting whether an allergic subject is likely to develop clinical or natural tolerance over time. The invention also relates to diagnostic methods and diagnostic kits employing the peptide biomarkers.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 4, 2022
    Assignees: AllerGenis LLC, ICAHN School of Medicine at Mount Sinai
    Inventors: Robert C. Getts, James Kadushin, Hugh A. Sampson, Luda Bardina, Galina Grishina, Gustavo Gimenez, Jing Lin
  • Patent number: 11208527
    Abstract: The present invention provides water soluble photoactive macromolecular complexes and methods for detecting an analyte in a sample by using a binding agent conjugated to a water soluble photoactive macromolecule.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 28, 2021
    Assignee: Beckman Coulter, Inc.
    Inventors: Arunkumar Easwaran, Sergei Gulnik
  • Patent number: 11209433
    Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: December 28, 2021
    Assignee: Becton, Dickinson and Company
    Inventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman D. Himel, IV, Rosemary B. Evans-Storms
  • Patent number: 11208444
    Abstract: The invention is the products and methods associated with purifying overexpressed recombinant recombinases from a host cell line resulting in an un-tagged protein of interest without any additional, non-native amino acids. The invention employs at least one DNA vector that co-expresses a tagged fusion protein and the recombinase protein with the recombinase protein having an affinity for binding to the tagged fusion protein. Isolation methods of the recombinase protein include the targeting of the tagged fusion protein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: December 28, 2021
    Assignee: Idea Seed, LLC.
    Inventor: Michael Longo
  • Patent number: 11202837
    Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: December 21, 2021
    Assignee: ANTIKOR BIOPHARMA LIMITED
    Inventors: Mahendra Persaud Deonarain, Gokhan Yahioglu, Ioanna Stamati, Savvas Saouros, Prashant Bhimrao Kapadnis
  • Patent number: 11193947
    Abstract: Described herein are methods for assessing the risk of cardiovascular disease in a subject in need thereof by detecting the presence of one or more cleavage products of the one or more natriuretic peptides over a period of time, wherein the presence of one or more cleavage products is indicative of an increased risk of the subject developing cardiovascular disease. Provided herein are compositions and kits comprising a non-natural natriuretic peptide comprising one or more D-amino acids. Also provided herein are methods of diagnosing a subject for a disease and treating the subject for the disease, wherein the method comprises the use of a non-natural natriuretic peptide comprising one or more D-amino acids.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 7, 2021
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Shenyan Zhang, Koen Raedschelders, Jennifer Van Eyk
  • Patent number: 11193940
    Abstract: The present invention relates to a sensor for the detection of Neurotrophic Factor (NF). The sensor, preferably a Screen Printed Electrochemical sensor (SPE), has a working electrode coated by a Molecularly Imprinted Polymer (MIP) imprinted by a NF. The invention also relates to a method for preparing such a sensor and comprising the steps of 1) formation of a cleavable linking layer on the working electrode of the sensor; 2) immobilization of NF molecules on the cleavable linking layer; 3) polymerization of m-PD on the working electrode of the sensor; and 4) cleavage of the cleavable linking layer thereby removing the NF molecules from the MIP layer.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: December 7, 2021
    Assignee: TALLINN UNIVERSITY OF TECHNOLOGY
    Inventors: Vitali Sõritski, Jekaterina Reut, Anna Kidakova, Andres Öpik
  • Patent number: 11192938
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 7, 2021
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Patent number: 11193929
    Abstract: A bi-epitope compound of formula I: in which: E1 and E2, identical or different, each separately represents a peptide sequence including at least one epitope of an analyte; X and Y, identical or different, each separately represents a linking arm, the carrier molecule is soluble and Z represents an amino acid derivative bearing a thiol function prior to the bonding of same with the carrier molecule. The compound may be contained in a composition, used as a control or standard in an immunoassay and associated method, and/or provided in a kit for implementing an immunoassay.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 7, 2021
    Assignee: BIOMERIEUX
    Inventors: Florence Bettsworth, Sandrine Busseret, Catherine Pothion
  • Patent number: 11185539
    Abstract: The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 30, 2021
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER (MHH)
    Inventors: Thomas Thum, Katharina Schimmel, Quoc-Tuan Do, Philippe Bernard
  • Patent number: 11181533
    Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: November 23, 2021
    Assignee: DIGNITY HEALTH
    Inventors: Jiong Shi, Peng Cheng Han